Vir Biotechnology (VIR) to Release Quarterly Earnings on Thursday

Key Points

• Vir Biotechnology is set to release its Q3 2025 earnings report on October 30, 2025, with analysts predicting a loss of ($0.70) per share and revenue of $1.9830 million.
• The company's last quarter earnings showed a loss of ($0.80) per share and revenue decline of 60.5% year-over-year, missing analysts' expectations significantly.
• Major shareholders have recently sold substantial shares, with insiders liquidating over $10 million worth of stock in the past 90 days, indicating potential concerns about the company's performance.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) is projected to issue its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($0.70) per share and revenue of $1.9830 million for the quarter. Individuals may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The firm had revenue of $1.21 million during the quarter, compared to analysts' expectations of $2.38 million. During the same quarter in the previous year, the company posted ($1.02) EPS. Vir Biotechnology's revenue for the quarter was down 60.5% on a year-over-year basis. On average, analysts expect Vir Biotechnology to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Trading Down 2.4%

Shares of NASDAQ VIR opened at $6.12 on Thursday. The stock has a fifty day simple moving average of $5.27 and a two-hundred day simple moving average of $5.28. Vir Biotechnology has a 1-year low of $4.16 and a 1-year high of $14.45. The firm has a market cap of $850.19 million, a price-to-earnings ratio of -1.53 and a beta of 1.27.

Insider Buying and Selling

In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf sold 466,242 shares of the firm's stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $6.05, for a total value of $2,820,764.10. Following the completion of the transaction, the insider directly owned 15,621,369 shares of the company's stock, valued at $94,509,282.45. This trade represents a 2.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Vicki L. Sato sold 22,000 shares of the business's stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $5.84, for a total value of $128,480.00. Following the transaction, the director owned 1,232,391 shares of the company's stock, valued at approximately $7,197,163.44. The trade was a 1.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,739,757 shares of company stock valued at $10,278,478 over the last 90 days. 16.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vir Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new position in Vir Biotechnology in the second quarter worth $35,000. Daiwa Securities Group Inc. raised its holdings in Vir Biotechnology by 2,200.6% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company's stock valued at $62,000 after buying an additional 11,773 shares during the last quarter. Focus Partners Wealth boosted its holdings in shares of Vir Biotechnology by 15.3% during the first quarter. Focus Partners Wealth now owns 19,317 shares of the company's stock worth $125,000 after purchasing an additional 2,566 shares during the period. Captrust Financial Advisors lifted its holdings in Vir Biotechnology by 39.7% in the 2nd quarter. Captrust Financial Advisors now owns 30,739 shares of the company's stock worth $155,000 after buying an additional 8,739 shares during the period. Finally, Cerity Partners LLC increased its position in Vir Biotechnology by 125.7% during the 2nd quarter. Cerity Partners LLC now owns 33,903 shares of the company's stock valued at $171,000 after purchasing an additional 18,882 shares during the period. Hedge funds and other institutional investors own 65.32% of the company's stock.

Wall Street Analyst Weigh In

VIR has been the subject of several research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vir Biotechnology in a research note on Tuesday, October 14th. Evercore ISI initiated coverage on shares of Vir Biotechnology in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $12.00 target price for the company. Raymond James Financial assumed coverage on shares of Vir Biotechnology in a research note on Friday, July 11th. They issued an "outperform" rating for the company. Bank of America raised shares of Vir Biotechnology from a "neutral" rating to a "buy" rating and boosted their price target for the company from $12.00 to $14.00 in a research report on Wednesday, August 27th. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research note on Monday, September 15th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.30.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.